Literature DB >> 12211096

Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy.

Yasuhiko Yamada1, Yoshiyuki Ohno, Yoshifumi Nakashima, Masato Fukuda, Risa Takayanagi, Hitoshi Sato, Fumito Tsuchiya, Yasufumi Sawada, Tatsuji Iga.   

Abstract

In the present study, we attempted to predict the risk of extrapyramidal side effects of a selective monoaminergic antagonist, risperidone, by analyzing the correlation between the dopamine D(2) receptor occupancy and the degree of extrapyramidal side effects of the drug. The occupancies of D(2) and 5-HT(2) receptors at various doses of risperidone were calculated by means of a receptor occupancy theory. The extrapyramidal side effects after administration of risperidone were attempted to predict by theoretical analysis of the correlation between the calculated occupancies and the evidence of extrapyramidal symptoms using a ternary complex model. The pharmacokinetic/pharmacodynamic analysis utilized the data concerning the pharmacokinetics of risperidone and 9-hydroxyrisperidone (active metabolite), their binding affinities with D(2) and 5-HT(2) receptors, and the clinical evidence of extrapyramidal symptoms (Extrapyramidal Symptom Rating Scale: ESRS), gathered from the literature. The mean occupancy of 5-HT(2) receptors after the administration of regular doses of risperidone was suggested to be more than 90%, whereas the mean occupancy of D(2) receptors varied between 50-80%, depending on the dose. The correlation between the occupancy of D(2) receptors and the extrapyramidal symptoms could be successfully analyzed with a ternary complex model, showing the predictability of the model for the extrapyramidal side effects of risperidone. Since the estimated risk of the extrapyramidal side effects varied with the dose, the present method of predicting the extrapyramidal side effects of risperidone may provide a basis for developing a rational dosing regimen for the drug. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12211096     DOI: 10.1002/syn.10111

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  5 in total

1.  An original pharmacoepidemiological-pharmacodynamic method: application to antipsychotic-induced movement disorders.

Authors:  Thi Thu Ha Nguyen; Antoine Pariente; Jean-Louis Montastruc; Maryse Lapeyre-Mestre; Vanessa Rousseau; Olivier Rascol; Bernard Bégaud; François Montastruc
Journal:  Br J Clin Pharmacol       Date:  2016-11-06       Impact factor: 4.335

2.  Effects of the atypical antipsychotics olanzapine and risperidone on plasma prolactin levels in male rats: a comparison with clinical data.

Authors:  Claire Rourke; Kathryn R Starr; Charlie Reavill; Sue Fenwick; Kim Deadman; Declan N C Jones
Journal:  Psychopharmacology (Berl)       Date:  2005-12-07       Impact factor: 4.530

3.  A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens.

Authors:  Zhu Li; Junji Ichikawa; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2003-03-28       Impact factor: 4.530

4.  Hyponatremia Following Antipsychotic Treatment: In Silico Pharmacodynamics Analysis of Spontaneous Reports From the US Food and Drug Administration Adverse Event Reporting System Database and an Updated Systematic Review.

Authors:  Faizan Mazhar; Vera Battini; Marco Pozzi; Elena Invernizzi; Giulia Mosini; Michele Gringeri; Annalisa Capuano; Cristina Scavone; Sonia Radice; Emilio Clementi; Carla Carnovale
Journal:  Int J Neuropsychopharmacol       Date:  2021-07-14       Impact factor: 5.176

5.  Theory-based analysis of clinical efficacy of triptans using receptor occupancy.

Authors:  Kentaro Tokuoka; Risa Takayanagi; Yuji Suzuki; Masayuki Watanabe; Yasuhisa Kitagawa; Yasuhiko Yamada
Journal:  J Headache Pain       Date:  2014-12-08       Impact factor: 7.277

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.